Skip to content

Pregnenolone

Pregnenolone is a precursor steroid hormone involved in the synthesis of various other hormones, including progesterone, estrogen, and testosterone. It plays a role in cognitive function, mood regulation, and stress response, making it relevant for longevity and health optimization. Its potential benefits include improved cognitive performance and mood stabilization.

Intelligence Profile

Research Papers

Research Papers and Clinical Trials

The research literature on pregnenolone spans several therapeutic areas, though many studies focus on its role as a precursor steroid hormone rather than as a direct therapeutic agent.

Recent Research Papers

Recent systematic reviews have examined pregnenolone's role in metabolic pathways, particularly in polycystic ovary syndrome (PCOS), where it appears as part of disrupted steroidogenic pathways. Other research has investigated pregnenolone's function in neurosteroid signaling, especially its role in modulating GABAergic neurotransmission in conditions like epilepsy.

Several 2026 studies have developed analytical methods for measuring pregnenolone and related steroids in various tissues, including skeletal muscle and follicular fluid. One notable study identified pregnenolone enrichment specifically in certain pituitary tumor lineages, suggesting potential biomarker applications.

Environmental health research has also examined how external exposures can affect pregnenolone and steroidogenic pathways, with implications for metabolic health.

Clinical Trials

The clinical trial evidence for pregnenolone includes several completed and ongoing Phase 1-2 studies:

Completed trials have investigated pregnenolone for:

  • Marijuana dependence (Phase 2, NCT02439814)
  • Chronic pain in military veterans (Phase 2, NCT01898013)
  • Mild traumatic brain injury in veterans (NCT00623506)
  • Stress and alcohol craving in alcohol use disorders (Phase 1, NCT03872128)

Currently recruiting is a Phase 2 trial examining pregnenolone for alcohol use disorder treatment (NCT05781009).

The clinical evidence base remains limited, with most completed trials being small-scale Phase 1-2 studies focused on neuropsychiatric and substance use conditions. Sample sizes and detailed outcomes from these trials are not provided in the available evidence.

Disclaimer: This information is for educational purposes only and should not be used as medical advice. Consult healthcare providers for personalized medical guidance.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.